Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CC-94676 |
Synonyms | |
Therapy Description |
CC-94676 is a ligand-directed degrader of AR that potentially decreases Ar signaling and tumor growth (Cancer Res (2024) 84 (7_Supplement): ND02). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CC-94676 | CC94676|CC 94676|AR Degrader CC-94676|BMS-986365|BMS986365 | Hormone - Anti-androgens 54 | CC-94676 is a ligand-directed degrader of AR that potentially decreases Ar signaling and tumor growth (Cancer Res (2024) 84 (7_Supplement): ND02). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04428788 | Phase I | CC-94676 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer | Active, not recruiting | USA | 0 |